Pancreatic cancer is an aggressive disease with high rates of disease-related mortality due to high rates of systemic disease spread. The role of radiation therapy for pancreatic cancer has been controversial to date. There have been significant advancements in effective systemic therapy regimens and radiation treatment delivery techniques, however, that are promising. This chapter aims to review all pertinent literature regarding the role of radiation therapy for pancreatic cancer.
- Chauffert B et al (2008) Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 19:1592–1599CrossRefPubMedGoogle Scholar
- Crane CH et al (2011) Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J Clin Oncol 29:3037–3043CrossRefPubMedPubMedCentralGoogle Scholar
- Hammel P, Huguet F, Van Laethem J-L, Goldstein D, Glimelius B (2013) Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: final results of the international phase III LAP 07 study. J Clin Oncol 31(18 suppl):LBA4003a. (201AD)CrossRefGoogle Scholar
- Klinkenbijl JH et al (1999) Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 230:776–782.; discussion 782–784CrossRefPubMedPubMedCentralGoogle Scholar
- Moertel CG et al (1981) Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: the Gastrointestinal Tumor Study Group. Cancer 48:1705–1710CrossRefPubMedGoogle Scholar